Claims for Patent: 10,016,534

Summary for Patent: 10,016,534

Title:	Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
Abstract:	The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.
Inventor(s):	Masters; David B. (Minneapolis, MN)
Assignee:	Gel-Del Technologies, Inc. (St. Paul, MN)
Application Number:	13/131,083
Patent Claims:	1. A vessel graft system comprising: one or more tube(s) including one or more components, at least one of the components including a first biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervate(s), the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents and formed into a tubular configuration; one or more threads, sutures and/or wraps positioned at one or more end(s) of one or more of the tube(s); the threads, sutures and/or wraps comprising one or more pharmacologically active agents and a biomaterial formed from a one or more precipitated amorphous thermoplastic biocoacervate(s), the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents, wherein the threads, sutures and/or wraps deliver the one or more pharmacologically active agents to an anastomosis site; and, a bioglue comprising a precipitated amorphous thermoplastic biocoacervate and one or more crosslinkers, the precipitated amorphous thermoplastic biocoacervate and one or more crosslinkers administered at the anastomosis site wherein the bioglue seals the threads, sutures and/or wraps at the anastomosis site. 2. The vessel graft system of claim 1 wherein the biocoacervates of the tube(s) and/or thread(s) are the same material. 3. The vessel graft system of claim 1 wherein the tube includes a structural scaffolding coated or encapsulated with the thermoplastic biomaterial. 4. The vessel graft system of claim 1 wherein the one or more primary proteins are selected from the group consisting of collagen, laminin, bone morphogenic protein and its isoforms that contain glycosaminoglycan binding sites, albumin, interleukins, epidermal growth factors, fibronectin, thrombin, aprotinin and antithrombin III. 5. The vessel graft system of claim 1 wherein the one or more glycosaminoglycans are selected from the group consisting of heparin, heparin sulfate, keratan sulfate, dermatin, dermatin sulfate, heparin-hyaluronic acid, chondroitin, chondroitin sulfate, chondroitin 6-sulfate, chondroitin 4-sulfate, chitin, chitosan, acetyl-glucosamine, hyaluronic acid, aggrecan, decorin, biglycan, fibromodulin, lumican and complexs thereof. 6. The vessel graft system of claim 1 wherein the tube further includes one or more secondary proteins. 7. The vessel graft system of claim 6 wherein the one or more secondary proteins are selected from the group consisting of fibrin, fibrinogen, elastin, albumin, ovalbumin, keratin, silk, silk fibroin, actin, myosin, thrombin, aprotinin and antithrombin III. 8. The vessel graft system of claim 1 wherein the one or more biocompatible solvents are selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols. 9. The vessel graft system of claim 1 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antiproliferative agents, angiogenesis inhibitors, angiogenic growth factors, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulant agents, genetic material, antithrombolytic agents, anticancer agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents and chemoattractants. 10. The vessel graft system of claim 9 wherein the one or more pharmacologically active agents are selected from the group consisting of paclitaxol, sirolimus, estradiol, dexamethazone, vitamin E, vitamin C, stem cells, superoxide dismutase, VEGF, FGF, EGF and cortizone. 11. The vessel graft system of claim 1 wherein the tube further includes one or more biocompatible additives. 12. The vessel graft system of claim 11 wherein the one or more biocompatible additives are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyalkenes, polyacrylates, bioceramic materials, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(alkylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly (amino acids), polycyanoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), glycosaminoglycans, bioceramic materials, insoluble proteins, proteins, amino acids, oils, fatty acids, salts, sugars, polypeptides, peptides, humectants, fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these. 13. The vessel graft system of claim 1 wherein the thermoplastic biomaterial is crosslinked with one or more crosslinking agents to form a crosslinked material. 14. The vessel graft system of claim 13 wherein the one or more cros slinking agents are selected from the group consisting of glutaraldehyde, 1,4-butandiol diglycidylether, formaldehyde, glyoxal, sebacic acid bis(N-succinimidyl) ester (DSS), p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4' azido-2' nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido]butylamine. 15. The vessel graft system of claim 1 wherein the biomaterial included in the tube(s) and/or the thread(s) comprises collagen, heparin, elastin and water. 16. A vessel graft system comprising: one or more tube(s) including one or more components, at least one of the components including a first biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervate(s), the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents and formed into a tubular configuration; one or more threads, sutures and/or wraps positioned at one or more end(s) of one or more of the tube(s); the threads, sutures and/or wraps comprising one or more components, wherein at least one of the component(s) including a biomaterial formed from a one or more precipitated amorphous thermoplastic biocoacervate(s), the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents; and a bioglue comprising a precipitated amorphous thermoplastic biocoacervate and one or more crosslinkers, wherein the bioglue seals the threads, sutures and/or wraps at an anastomosis site. 17. The vessel graft system of claim 16, wherein one or more threads, sutures and/or wraps further comprises one or more pharmacologically active agents and wherein the threads, sutures and/or wraps delivery the one or more pharmacologically active agents to the anastomosis site.

Details for Patent 10,016,534

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	December 29, 1993		2029-11-17